Baidu
map

JCO:这种癌也被过度诊断了?CSCO专家呼吁为其改名!

2022-04-26 MedSci原创 MedSci原创

专家认为取消GS6的癌症标签将极大地改善个人和公共健康。而这类患者需要做的只是采取积极监测,而无需立即采取治疗。

前列腺特异性抗原(PSA)是检测前列腺癌的重要指标,然而PSA筛查对前列腺癌(PCa)仍有很大争议,主要是因为不清楚降低转移率和癌症死亡率的主要好处是否值得过度诊断、过度治疗和潜在的治疗相关疾病的风险。

导致过度诊断和过度治疗的一个主要因素是将前列腺中特定的低级细胞变化模式定为癌症。近期,来自CSCO的专家在《临床肿瘤学杂志》(Journal of Clinical Oncology)发文指出,低级别前列腺癌不应该再被称为癌症。对这些病变进行简单的术语修改,并去掉癌症的标签,将大大减少过度诊断和过度治疗,并明显改变PSA筛查的成本-效益计算。

过度诊断流行病的根源在于50岁以上的男性中>30%(到80岁时>60%)会出现组织学PCa,因为如果一个人活得足够长,几乎所有的前列腺都会最终发展出微小的PCa。病理学结果GS6(即Gleason评分为6,为低级别)是一种自然的、与年龄有关的组织学观察,被人为地定义为一种疾病,不知道会引起症状或转移,但矛盾的是导致侵入性监测或治疗。这些担忧是导致美国预防服务工作组在2012年明确不鼓励PCa筛查的一个主要因素,特别指出了对 "微小的、分化良好的病变......不太可能有临床意义 "的常见诊断和治疗。

虽然GS6符合癌症的病理标准(侵入基质),但如果没有同时存在更高等级的疾病(GS≥7;即等级组≥2),它实际上不可能侵入邻近的局部结构或发生转移。当手术切除前列腺并术后证实为GS6时,尽管癌症通常已存在多年,甚至几十年,基本上100%不会发生转移。当癌症相关的死亡率接近0%,甚至在没有治疗的情况下也是如此,是时候应考虑修改筛查、诊断、管理和术语模式。

此外,无论医生花多少时间来淡化GS6诊断的重要性或强调低风险,"你得了癌症 "这句话对大多数男性和他们的家人都有强大的心理影响。

GS6患者15年内转移/死亡率低于1%

尽管与癌症相关的风险可以忽略不计,但PCa的诊断与抑郁症和自杀的风险增加有关,即使是低级别的PCa。同时,过度治疗往往会带来性功能障碍或尿失禁等副作用。而既往研究结果显示,低级别前列腺癌患者15年内转移/死亡率甚至低于1%。

因此,专家认为取消GS6的癌症标签将极大地改善个人和公共健康。而这类患者需要做的只是采取积极监测,而无需立即采取治疗。

参考文献:

Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. https://ascopubs.org/doi/full/10.1200/JCO.22.00123

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-12-11 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-07-22 走,走走

    同感

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-04-26 weigq

    甲状腺癌是否也存在类似情况?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-04-26 ms5000000686165165

    学习

    0

相关资讯

Radiology:多参数MRI在诊断前列腺导管腺癌中的价值

前列腺导管腺癌(DAC)是前列腺癌的第二大组织学亚型,大多数DAC是与PAC混合发生的肿瘤。

Radiology:对DWI的深度学习重建提高了前列腺成像的图像质量

深度学习重建(DLR)技术已被引入临床以改善MRI扫描质量,对改善图像质量和诊断性能的效用已经在MR冠状动脉造影和膝关节、盆腔和脑部成像中得到证实

Br J Cancer:5-氨基酮戊酸增加线粒体活性氧的产生降低前列腺癌的放疗抗性

5-ALA联合放射性疗法的治疗策略能够提高放疗对前列腺癌的治疗效果

英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见

镥 (177Lu) vipivotide tetraxetan 联合 SOC 组的中位 OS 为 15.3 个月,而 SOC 单独组为 11.3 个月。

Lancet Oncol:大剂量放疗+长期雄激素剥夺治疗前列腺癌的10年随访结果

大剂量放疗+长期雄激素剥夺治疗可改善高危型前列腺癌患者预后

拓展阅读

Eur Urol Oncol:PSMA PET/CT联合MRI对接受根治性前列腺切除术的前列腺癌患者进行局部分期的附加价值

与MRI相比,PSMA PET/CT在检测EPE方面的灵敏度较低。然而,将PSMA PET信息添加到MRI中可以提高对EPE和SVI检测的灵敏度。

Science:一种新的细胞死亡形式—— triaptosis(三磷酸肌醇凋亡)

前列腺癌(PC)是男性中最常见的癌症,预计到2024年,美国将有超过299,000例新增病例。这些男性中的大多数将出现缓慢生长的疾病,并可能转变为危及生命的PC,对现有的所有治疗方案产生抗药性。因此,

Eur Urol:一项前瞻性、非劣效性、非随机HIFI试验比较了全腺体或次全高强度聚焦超声与根治性前列腺切除术

全腺体或次全高强度聚焦超声(HIFU)与RP的中期STFS结果相当。HIFU治疗后患者的尿失禁和勃起功能障碍程度较轻。

Nature:破解前列腺癌免疫治疗耐药难题:SPP1hi-TAMs成为全新治疗靶点

前列腺癌中mCRPC对免疫检查点抑制剂疗效不佳,研究发现SPP1hi-TAMs随疾病进展富集,通过腺苷信号通路致免疫治疗耐药,阻断腺苷A2A受体联合治疗可增效,还探讨其在精准医学等方面意义。

European Radiology:定量MR指纹在前列腺癌患者转移性骨T1和T2测量中的重复性

采用弥散加权和Dixon成像的全身MRI (WB-MRI)已成为转移性骨病的潜在反应生物标志物。骨疾病的表观扩散系数(ADC)已被证明在有效治疗后显著增加。

Eur Urol Open Sci:前列腺癌雄激素剥夺疗法是否会影响生存相关的身体成分水平

本研究确定了前列腺癌男性患者在接受雄激素剥夺治疗期间肌肉流失和脂肪组织增加与全因死亡率相关的阈值。这些阈值有助于识别ADT 6个月后身体成分发生显著变化的患者,并指导干预措施以改善身体成分。

Baidu
map
Baidu
map
Baidu
map